We recently compiled a list of the 10 Best Quality Stocks to Buy According to Analysts. In this article, we are going to take a look at where Merck & Co Inc. (NYSE:MRK) stands against the other quality stocks.

Income-Focused Investing

The stock market has seen a notable 20% increase year-to-date, but as it approaches the seasonally volatile months leading up to Election Day, potential volatility is expected. The S&P 500 has historically pulled back 5% to 10% around election time but tends to recover afterward.

Instead of cashing out, investors are encouraged to take advantage of any market pullbacks. Historically, when the Fed cuts rates without an impending recession, it creates a favorable environment for broader market performance. Mona Mahajan, Edward Jones senior investment strategist, recently appeared on CNBC to discuss her similar sentiment on these latest market trends, and where investors can find opportunities right now. We talked about this in our article about the 10 Best WallStreetBets Stocks To Buy Right Now, here’s an excerpt from it:

“When asked if investors should consider cashing out and taking a holiday for the remainder of the year, Mahajan advised against such a move. Instead, she suggested that if there are pullbacks or corrections in the market, it would be prudent to lean into those opportunities… Additionally, rate cuts typically lead to expanded valuations, particularly for sectors that have lagged behind in this regard. She emphasized that lower borrowing costs from Fed rate cuts would benefit both consumers and corporations.

In terms of investment strategies during potential downturns, she recommended focusing on cyclical sectors such as utilities and industrials while also maintaining exposure to technology and the artificial intelligence sectors. Mahajan underscored that diversification would be key over the next 12 to 18 months.”

Global Investment Strategist at ProShares Advisors, Simeon Hyman, appeared on CNBC on October 2 to emphasize ‘income’ as a key focus, highlighting the opportunity in fixed-income markets, which could provide 10-15% returns if geopolitical tensions worsen. He thinks that the US economy is stronger than the rest of the world despite tensions.

Simeon Hyman emphasized the importance of the term ‘income’ in the context of current market conditions, noting that the market was just 1% off its all-time highs. This situation presents a salary cut for income-oriented investors, highlighting the challenges they face. However, the fixed-income market offers a silver lining; it currently provides enough yield to cushion against worsening geopolitical tensions. For instance, the yield on the 10-year bond is nearly 4%, and there is potential for it to drop to 3% or lower if significant negative events occur. This scenario presents an opportunity for investors to realize gains of 10% or 15% on bonds in a tumultuous environment, a situation not seen in over a decade.

Despite the current market being down by 3.7%, which is slightly less than 4%, Hyman insisted that rounding was at play. He expressed surprise at this performance given ongoing geopolitical tensions but pointed out that positive economic news in the US persists. Specifically, there has been a 50-basis point cut and indications of a soft landing for the economy. A month-over-month increase of just 0.1% suggests that if one can overlook geopolitical issues, the US economy is faring better than many others globally and remains on solid economic footing.

Additionally, Hyman proposed a covered call strategy focused on the Russell 2000 index, which has been underperforming compared to the S&P 500. He described this strategy as beneficial because it allows investors to generate income that could offset recent losses while maintaining a bullish position in small caps. Historically, rate cuts have positively impacted small-cap stocks, and this strategy enables investors to capitalize on that trend while also generating income through covered calls.

For risk-averse investors, the current emphasis on fixed-income markets as a viable investment option aligns well with the insights shared by Simeon Hyman, who highlighted the potential for 10-15% returns in bonds amid geopolitical tensions. Additionally, they may also explore quality stocks with reliable growth histories, which can provide stability in uncertain market conditions, similar to the defensive strategies Hyman suggested. As investors try to track stock performances to find strategies, we’re here with a list of the 10 Best Quality Stocks to Buy According to Analysts.

Methodology

To compile our list, we first sifted through Vanguard U.S. Quality Factor ETF holdings to find the ones with an upside potential of over 15% as of October 4, 2024. We then selected the 10 stocks that were the most popular among elite hedge funds and that analysts were bullish on. The stocks are ranked in ascending order of their analysts’ upside potential.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).

Merck & Co Inc. (NYSE:MRK)

Average Upside Potential: 27.06%

Number of Hedge Fund Holders: 96

Merck & Co Inc. (NYSE:MRK) delivers innovative health solutions through its prescription medicines, vaccines, biologic therapies, and animal health products. It has a strong focus on research and development, and its products are used to treat a wide range of diseases and conditions, including cancer, infectious diseases, cardiovascular diseases, and neurological disorders.

Its growth is partly due to a patent for KEYTRUDA that will expire in 2028. This could affect its growth in the future. Merck & Co Inc. (NYSE:MRK) bought Elanco’s aqua business to become a leader in animal health. In July, it bought EyeBio to enter the ophthalmology market and develop treatments for eye conditions. It also bought Prometheus Biosciences, which will help them develop new and advanced treatments.

Recently, the company got FDA approval for its new pneumococcal vaccine, CAPVAXIVE, for adults. It also got FDA approval for the WINREVAIR vaccine for adults with pulmonary arterial hypertension. This vaccine made over $70 million in sales in Q2 2024, with 40% coming from patient doses.

Its revenue grew by 7.16% in Q22024. Human Health grew by 11%, Animal Health grew by 6%, and KEYTRUDA, the cancer drug, grew by 21%. Sales of GARDASIL and VAXNEUVANCE also increased. The company is growing quickly in other countries. Buying Harpoon Therapeutics will help it develop new cancer treatments. All of these factors position Merck & Co Inc. (NYSE:MRK) well for continued success in the global healthcare market.

Regarding Merck & Co., Inc. (NYSE:MRK), Baron Funds’ Baron Health Care Fund made the following statement in its investor letter for the first quarter of 2024:

“Global pharmaceutical company Merck & Co., Inc. (NYSE:MRK), Inc. contributed to the continued growth of Keytruda, the company’s key asset and the leading immuno-oncology agent used to treat a variety of cancers. The FDA’s late March approval of pulmonary arterial hypertension drug sotatercept also drove share gains. We retain conviction as Merck has started to transition from prioritizing its Keytruda franchise to building a more diversified business, with a focus on the Gardasil vaccine, pneumococcal vaccine development, and cardiovascular drug development, well in advance of the scheduled expiration of patent protection/exclusivity rights.”

Overall MRK ranks 1st on our list of the best quality stocks to buy according to analysts. While we acknowledge the potential of MRK as an investment, our conviction lies in the belief that AI stocks hold great promise for delivering high returns and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than MRK but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

READ NEXT: $30 Trillion Opportunity: 15 Best Humanoid Robot Stocks to Buy According to Morgan Stanley and Jim Cramer Says NVIDIA ‘Has Become A Wasteland’.

Disclosure: None. This article is originally published at Insider Monkey.